According to the immunohistochemistry data, we classified the glioma patients into four groups by the protein levels of ANXA2 and GPC1: (1) patients with both low ANXA2 and GPC1 levels (ANXA2low/GPC1low patients) ((n = 69); (2) those with low ANXA2 and high GPC1 levels (ANXA2low/GPC1high patients) (n = 54); (3) those with high ANXA2 and low GPC1 levels (ANXA2high/GPC1low patients) (n = 18); and (4) those with both high ANXA2 and GPC1 levels (ANXA2high/GPC1high patients) (n = 23) (Fig. 4A–H). Here, GPC1 is linked to central nervous system cancer.